|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Blue Light Cystoscopy Delays Time To Recurrence in NMIBC Patients Treated in a Real-World Setting
|
|
Siamak Daneshmand, MD
|
| Sam Chang and Sia Daneshmand explore the impact of Cysview blue light cystoscopy on cancer recurrence. Dr. Daneshmand presents a comprehensive registry study from USC which shows significantly lower recurrence rates in patients examined with blue light cystoscopy, when compared to a white light patient group.
|
|
|
|
|
|
|
|
|
|
|
|
| Establishing Nadofaragene Firadenovec in a Large Urology Practice |
| Daniel Canter, MD |
| Ashish Kamat and Daniel Canter discuss the role of nadofaragene firadenovec in the treatment of non muscle-invasive bladder cancer. Dr. Canter, drawing from his firsthand experience in Phase 1, 2, and 3 trials, highlights the therapy's tolerability and its efficacy, particularly noting its superior administration schedule compared to BCG. |
|
|
|
|
|
|
|
|
|
|
|
|
Bladder Cancer's Impact on Daily Life and Employment: A Global Perspective
|
Lydia Makaroff, Ph.D., and Lori Funk-Cirefice
Ashish Kamat is joined by Lori Cirefice and Lydia Makaroff who discuss the findings of the Global World Bladder Cancer Patient Coalition Survey, focusing on the impact of bladder cancer on daily life and caregivers. The survey, which garnered nearly 1,200 responses from 45 countries, reveals significant financial and emotional strain on patients and their careers.
|
|
|
|
|
|
|
|
|
|
|
| Study of Real-World Treatment Patterns and Adherence to BCG in the Context of Guideline Recommendations for Patients with High-Risk NMIBC |
| Andrea Ireland, Ph.D. |
| This study examined real-world treatment patterns and adherence to BCG in high-risk NMIBC patients. Despite BCG being recommended as first-line treatment for these patients, shortages in the US have impacted outcomes. The study found that while most NMIBC patients received adequate BCG induction, maintenance was often inadequate, leading to subsequent treatments, with those having CIS being more likely to undergo cystectomy, indicating a higher risk of progression in this subgroup. |
|
|
|
|
|
| Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis - Beyond the Abstract
|
| Aleksander Ślusarczyk, MD, PhD
|
| This paper presents an in-depth analysis of cancer-specific survival in patients with NMIBC, utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database. It highlights significant differences in CSS among different NMIBC stages, with T1HG and Tis showing the highest cancer-specific mortality rates. The study underscores the importance of considering both clinical and socioeconomic factors in NMIBC prognosis and management decisions, advocating for improved risk stratification and addressing healthcare disparities.
|
|
|
|
|
|
|
|
|
|
|
| Blue Light Cystoscopy Delays Time to Recurrence in Non-Muscle Invasive Bladder Cancer Patients Treated in a Real-World Setting |
| Siamak Daneshmand, MD |
| Siamak Daneshmand presented findings from a study assessing the impact of blue light cystoscopy on recurrence rates in non-muscle invasive bladder cancer (NMIBC) patients. The study, based on data from the United States Blue Light Cystoscopy with Cysview Registry, revealed that patients undergoing blue light cystoscopy had significantly lower recurrence rates compared to those undergoing white light cystoscopy. |
|
|
|
|
|
| Reasons for Refusal of or Ineligibility for Radical Cystectomy in Patients with BCG–Unresponsive High-Risk NMIBC from the SunRISe-1 Study
|
| Joseph Jacob, MD
|
| Joseph Jacob presents findings from the SunRISe-1 study, focusing on reasons for refusal of or ineligibility for radical cystectomy in patients with BCG-unresponsive high-risk NMIBC. The study highlighted that over 90% of patients in the TAR-200 monotherapy cohort refused radical cystectomy, with the primary reasons being a preference for bladder preservation and concerns about quality of life.
|
|
|
|
|
|
| ABLE-41: Nadofaragene Firadenovec-Vncg Early Use and Outcomes in a Real-World Setting in the United States |
| Siamak Daneshmand, MD |
| Sia Daneshmand discusses the trial design of ABLE-41, which evaluates the early use and outcomes of nadofaragene firadenovec-vncg in a real-world setting in the United States for patients with BCG-unresponsive NMIBC. ABLE-41, a non-interventional study, aims to assess effectiveness, safety, patient experiences, and other outcomes in approximately 200 patients from various urology sites. |
|
|
|
|
|
| RC48-ADC Versus BCG in Adjuvant Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer with HER2 Over-Expression: A Real-World Retrospective Study
|
| Haoyang Liu, MD
|
| Haoyang Liu presented real-world findings comparing RC48-ADC to BCG in adjuvant treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) with HER2 over-expression. While RC48-ADC demonstrated a 100% 12-month recurrence-free survival rate with manageable adverse events, BCG-treated patients had a 57.6% rate.
|
|
|
|
|
|
|
|
|
|
|
|
